SK Bioscience Co Ltd
KRX:302440

Watchlist Manager
SK Bioscience Co Ltd Logo
SK Bioscience Co Ltd
KRX:302440
Watchlist
Price: 51 200 KRW -3.4% Market Closed
Market Cap: 4T KRW
Have any thoughts about
SK Bioscience Co Ltd?
Write Note

SK Bioscience Co Ltd
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

SK Bioscience Co Ltd
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
SK Bioscience Co Ltd
KRX:302440
Short-Term Investments
â‚©1.1T
CAGR 3-Years
84%
CAGR 5-Years
63%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Short-Term Investments
â‚©167.2B
CAGR 3-Years
84%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Green Cross Corp
KRX:006280
Short-Term Investments
â‚©1.8B
CAGR 3-Years
-56%
CAGR 5-Years
-20%
CAGR 10-Years
-29%
H
Hugel Inc
KOSDAQ:145020
Short-Term Investments
â‚©271.9B
CAGR 3-Years
-18%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Short-Term Investments
â‚©101.8B
CAGR 3-Years
16%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Short-Term Investments
â‚©126.7B
CAGR 3-Years
-13%
CAGR 5-Years
25%
CAGR 10-Years
N/A
No Stocks Found

SK Bioscience Co Ltd
Glance View

Market Cap
3.9T KRW
Industry
Biotechnology

SK Bioscience Co Ltd., a remarkable enterprise carved out of the South Korean corporate landscape, operates at the dynamic intersection of biotechnology and pharmaceuticals. A part of the larger SK Group, one of Korea's leading conglomerates, the company was officially established in 2018 from SK Chemicals' life sciences division. Its primary focus is on developing and manufacturing vaccines, serving both public health needs locally and globally. The company has swiftly gained prominence for its role in the COVID-19 pandemic, particularly with the production of vaccines in collaboration with significant players such as AstraZeneca and Novavax. This strategic engagement loop has positioned SK Bioscience not only as a critical player in health crises management but also as a pivotal contributor to global health security. At the heart of SK Bioscience's business model is its ability to leverage cutting-edge research and robust manufacturing capabilities. The firm generates revenue through various channels, including product sales of its vaccines and other pharmaceuticals, contract manufacturing services, and partnerships with global entities, allowing it a diversified income stream. Its adeptness in innovation, underpinned by a strong R&D framework, ensures a steady development pipeline, supporting long-term growth ambitions. Through these strategic activities, SK Bioscience aligns itself with the SK Group’s broader commitment to social value and environmental, social, and governance (ESG) principles, fortifying its reputation as a company that not only seeks financial success but also endeavors to wield a positive global impact.

Intrinsic Value
37 060.28 KRW
Overvaluation 28%
Intrinsic Value
Price

See Also

What is SK Bioscience Co Ltd's Short-Term Investments?
Short-Term Investments
1.1T KRW

Based on the financial report for Dec 31, 2023, SK Bioscience Co Ltd's Short-Term Investments amounts to 1.1T KRW.

What is SK Bioscience Co Ltd's Short-Term Investments growth rate?
Short-Term Investments CAGR 5Y
63%

Over the last year, the Short-Term Investments growth was -9%. The average annual Short-Term Investments growth rates for SK Bioscience Co Ltd have been 84% over the past three years , 63% over the past five years .

Back to Top